Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Detection Technology, Half-yearly report 2026

By Inderes8/6/2026, 10:00 AM
Detection Technology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Hannu Martola
00:02 - 13:15

Good afternoon. Welcome to follow Detection Technology's second quarter result announcement. My name is Hannu Martola. I am the President and CEO of Detection Technology, and I am pleased to present the results. In the second quarter, we reached sales of 25.6 million, which is a 5.1% growth year-on-year, and reached an EBITA of 1.8 million, which is slightly better than last year's 1.7 million, with an EBITA percentage of 7.1%, again slightly better than the year before. Where did it come from? So the growth continued. It was very much driven by both medical applications and TFT; the good news is that TFT growth has now started also in the Western markets. But then in total, China weighed on both our security and industrial sales. Total industrial sales were -6%. Sales of line scan products in APAC, specifically China, declined, but TFT sales grew in APAC as well as in all geographical markets for industrial and medical applications. Strong growth of 21% was driven by global CT demand. But the TFT delivers for medical. We started to deliver those security sales, which declined 8%. And this is a bit controversial because we had good growth both in Europe and the Americas in Western markets. Good growth also in APAC outside China, but the China security sales declined. The total outcome was -8%. Despite this, our global market share remains unchanged. We are a little bit stronger in the Western markets. And then in China, markets are a little bit different, as some of our customers are making products for themselves by using two sources: us and in-house. Net sales by quarter. We see here the past three or four years, including the first and second quarters of 2026. This year is up about 9.9% together. Also, EBITDA is slightly better than the reference period, which was 7.1%. Then, let us go into the regional business units. Americas, representing 7% of our sales, grew by a healthy 15%. That was driven largely by security. And I think this is also good news that in the Americas, we have had some decline in history and some structural changes. Now it is starting to grow. APAC, representing 72% of our sales, grew 2%. China declined, but overall, EMEIA represents 21% of growth. We saw nice growth of 15%. And EMEIA also was very much driven by security. I must note here also that we have some shift in security sales from Europe to outside China, in Asia. So that is also affecting these numbers. Then by applications, industrial was -6% altogether, while medical grew 21% to 13 million euros. And security, which represents 20% of our sales, is down 8% altogether. Looking at the first six-month numbers, I believe. We saw 9.1% growth. EBITA was 8.2% and €4.2 million. And these are the results for the first six months. Regional business unit split. Americas saw 21% growth. APAC 6% growth. And Europe, Middle East, India, and Africa saw 18% growth. And the same six months by application. Industrial business saw growth of 6%. Medical growth of 19% and security flattish at -1.5%. Then, looking at the key results and numbers, a couple of things that I would like to highlight. I think the profitability here, 7.1%, is very much explained through the product mix. That is something that must be noted. It was quite heavy on medical, and that is affecting the numbers. We also have high fixed costs due to the ongoing construction of the factory in India. Enablers for future growth on the investment side that stick out are investments of 3.3 million. We made long-term investments into R&D capabilities and competencies, and therefore, our cash flow was negative 600,000 euros. Two reasons. One is the long-term investments. Then, the other factor is an increase in inventory. Return on assets. Net assets is still quite nice, 19.9%. I expect that for the future, we can improve that. Next, I want to go through what we have done in our strategy execution. We have four cornerstones. That is the base regarding our legacy technologies and doing everything better. Regarding our growth areas, we are focused on TFTs, added-value subsystems, and investing in new, long-term technology, all built on the foundation of a better-performing organization and team, as well as ensuring more satisfied, successful customers through easy-to-use products and services from Detection Technology. I think this is quite interesting. This is the 65 million target, representing additional sales of 65 million to be reached by 2030. We have divided this, and this is something we also published at our Capital Markets Day a bit over a year ago. We have divided this into the areas for TFT: into the medical industrial CT line scan, into security CT line scan, and then into security cargo; TFT, by the way, represents one third of this growth. This is very important for us. So we have now launched more than 60 TFT products. We have launched the world's largest flat panel 43108 and its little brother 4386, which is even faster but slightly shorter. We have introduced new IGZO-TFT products for both EV battery, energy storage, and dental applications. We have launched AIDA for more value-added subsystem hardware. Software detector systems. X-ACE for high-speed medical CT. We launched AIDA for low-cost security and industrial applications. And then we have in our pipeline new both low-cost and high-performing CT products, both for medical and security. We launched X-Cargo, which is a very fast detector, especially for trains and cargo detection. And all these together are helping us now to reach our target of 65 million in additional revenue. We are working on developing new photon counting technology, which boosts the growth even higher later on. And then we have the enablers for doing this. We have opened a new sales and production site in India. And by the way, it has just been granted a medical device manufacturing license in India. It is very fresh news. We started a new site in Shanghai, not only for a better environment for our R&D employees, sales, and administration there, but especially for new facilities for testing of products, providing much greater capacity. And then expanding the European origin capability, manufacturing in Oulu, which is helping us further into especially defense area in the Western world. On TFT sales, we saw a nice growth of 20% for the first half, and I believe it was 25% for the second quarter. But the notable thing here is that actually now TFT starts to be 10%, or one-tenth of our revenues. And out of this, roughly 10% to 20% is already coming from outside of China. We are now moving ahead well with our strategy, execution, and plans. We have seen growth in industrial applications. All regions for TFT deliveries for medical applications have started. And if we look at the order backlog. So regarding future orders, we have growth in all regions and it looks quite nice. And the most important foundation here is that now we have the world's best set of fast and large single-glass flat panel detectors. This is extremely important, especially for the defense and weapons industry. And to back that up. Here are the two new flat panel products. We have X-Panel 4308 and 4386, and one of our customers, a representative from Fraunhofer IIS, which is the largest research institute in Europe, stated the following. I think Fraunhofer has some 35,000 research people. He said that this is a real game changer for industrial CT, and we are now stepping into the era of quality. Everybody knows the word drone. Stepping from missile to high-volume drone manufacturing requires quantity, throughput, and quality. And that is where this X-ray technology steps in. So defense drives the demand for fast and large-scale scanning for high throughput and quality. And this position has now been verified following these launches. So several customers have been verifying our products. Now we need to sell. We are number one in high-value industrial defense inspection, utilizing large dynamic panels. Okay. Stepping from products into reporting, this is something that we are now planning. We are now planning to move into IFRS reporting for the first time starting from the fourth quarter of this year. And this would then put us into the same framework with all our peer group. The transition date is 1st of January 2025, and we are reporting on the fourth quarter of 2026 as informed. And this is then helping especially the analysts and the financial community to really come up with comparable financial numbers. I would bet that it is more probable that our results will be a little bit improved than vice versa. But let's see when we finalize the planning work. Then, what do we see for the future? In the very short term, we see growth. We see growth for the third quarter and the fourth quarter. Probably the growth for the second half will be similar to the second quarter, with industrial and medical applications expected to grow, but security declining a little bit. So the official guidance for the third and fourth quarter is growth. The financial targets. Our mid-term financial targets remain the same: 10% net sales growth, 15% EBITA margin, and a 30% to 60% dividend payout ratio. So this is in a nutshell our performance for the second quarter, and we would be very happy to answer any questions if they may arise. Thank you.

Nick
13:19 - 13:52

Hello, this is Nick from CIB. Thank you for the presentation. I have a couple of questions, and I will go one by one. Starting with security sales, regarding both the outlook and sales in Q2. So, you highlighted that you are not expecting sales to grow due to Chinese weakness and also some fluctuation in the EMEIA market. Can you elaborate on the reasoning behind the EMEIA market performance?

Hannu Martola
13:53 - 15:12

I think if I look first at the Western market and so on. We know that our customers have new orders. We know that we have in our order pipeline, for example, products that will end up in US airports and so on. So overall, we see growth. Of course, there can be some quarterly adjustments and so on. But I mean, that market is growing and we expect to see growth in APAC. Also, outside of China, we see growth. But then there is the China security market. It is of high probability. It is still declining. The share of our revenues. When I refer to companies that have headquarters in China, I am also including Western companies operating in China. I am not talking about those types of companies whose headquarters are in China, and many of them, by the way, are government-related companies. The share of our total sales has been constantly declining. But that also means that the impact of it will be getting less. Long-term, we also see growth in these China-related headquarters. It is just that, for example, there are not very many investments in China in security. And also after the price erosion, let's say the market size has been changing.

Nick
15:13 - 15:19

Okay. So, that is basically the reason you are not expecting growth in Q3 is due to China.

Hannu Martola
15:20 - 15:20

Very much so.

Nick
15:20 - 15:26

Yeah. You also mentioned the in-housing trend from a couple of your clients.

Hannu Martola
15:26 - 16:10

If we look at history, we have had a very strong position in those days. Also, China was by far the biggest security market in the world, probably bigger than all the other countries counted together in the past. We do not think that will return in that way. So the picture has changed. Also, we almost had a monopoly. We were winning almost every single deal. And we were the first ones, and we were ready, and so on. And now it is becoming more of a normal type of business where customers might use two suppliers for risk mitigation, etc. These kinds of things. And this has been the journey there.

Nick
16:11 - 16:31

And that concerns China. Yes. Okay. Thank you. Then, on the medical side, you showed strong growth there. So, can you elaborate a bit? Was it between China and markets outside China, and how sustainable is the growth rate you are currently having there?

Hannu Martola
16:31 - 17:19

Right now, it looks quite sustainable. Nothing is, of course, everlasting. Nothing is everlasting. But I mean, the thing is, we also know that both GE Healthcare and Siemens have come out with second-quarter results. They have had quite nice results in the imaging sector, which is CT, which is the most important, biggest, and the highest profit maker there. So this is global. It is a little bit different if we consider China the global hub for medical. Let's see. Will that change because of India and so on? But right now, most of the equipment is made in China because of the super competitive supply chain. Part of the equipment will stay there. And answering your questions on growth. We see growth in basically all markets for computed tomography.

Nick
17:20 - 17:45

Okay. Good. Thank you. And then the last one from me, your business model tends to be scalable. While you are now guiding for or expecting medical sales to grow and security sales to decline. So probably the mix will be a bit weaker also in H2. So should we expect relative profitability to improve in H2?

Hannu Martola
17:46 - 18:24

Profitability improves when our revenues increase. Of course, product mix is also something that has an effect. I think from the profitability point of view, medical is high volume. The margins are there. Smaller security volumes are smaller, but the margins are a little bit better there. And then also, if we look at the TFT business overall, the margins are quite okay globally. Of course, there is big variation in the different segments and also the markets.

Nick
18:25 - 18:28

All right. Thank you. That is all from me.

Patrick Campbell
18:33 - 18:45

Hi. It is Patrick Campbell from Nordea. You completed some investments in Q2 related to the production process. Could you perhaps explain the rationale behind these investments?

Hannu Martola
18:46 - 19:07

Well, I think the Q2 investments are, in a way, threefold. We have production investments to improve capacity and also quality and automation. And then we have investments for long-term R&D.

Patrick Campbell
19:08 - 19:19

All right. Thank you. Looking ahead, will further similar investments be needed in H2? And if so, what is the size of these investments?

Hannu Martola
19:20 - 19:38

Probably the long-term R&D investments are not something that are with us every quarter. So we will see that coming down, though production capacity needs to be monitored. Compared to our revenues, our investments in production are fairly small.

Patrick Campbell
19:38 - 19:56

All right. Thank you. And then maybe on component availability, which you mentioned earlier, and now you continue to grow inventories. So, what kind of cost increases have you seen? Have you seen on the component side, and what is being done to mitigate the impact?

Hannu Martola
19:57 - 20:19

I think if we look at our P&L, you do not see very much of the impact of the cost increases. There is a little bit of cost increase there, but we have been able to mitigate those by taking on more value-added work in scintillator pixelation. And that is relating to the investments also in production and factory.

Patrick Campbell
20:21 - 20:49

All right. Thank you. And then maybe just another one on margins. So obviously the weight of medical sales has increased quite a bit. And now we are going into H2. So how should we think about the margin levels towards the end of the year? Should we think about a similar sequential pickup despite the higher medical sales or should we think about lower underlying margins as a whole?

Hannu Martola
20:50 - 20:57

Probably the mix gets a little bit less medical-heavy overall if we look from a margin perspective.

Patrick Campbell
20:58 - 20:59

All right. Thank you.

Ewa
21:07 - 21:42

Hi, this is Ewa from India. Another question about margins. I am just wondering about the TFT flat panels as they are the growth driver for the future. Also, I believe that 20% of the sales were coming from outside of China. If I understood correctly, how much better are the margins there? And overall, how is the margin profile? Is it somewhere around the middle of this offering? I'm wondering how the mix will change when the TFT panels are growing faster than the other sales?

Hannu Martola
21:42 - 22:27

I think regarding the TFT margin, first of all, we believe it will be improving overall. But if we look at the application, it probably behaves a little bit similarly to our other businesses. So it is also dependent very much on volumes. Some customers are purchasing in large volumes. There are different types of contracts compared to someone who is just buying a small volume. If we then think of, let's say, an application, for example, for defense. These products are under quite a lot of stress because of radiation. These need to be replaced even every eight months. So we will see a little bit of a consumable type of behavior for that business.

Ewa
22:29 - 22:52

Well, this is actually another question that I was wondering about. The defense opportunity seems pretty clear. And as you said, there is going to be a lot of quantity coming and you are in a good position. Could you quantify a little bit what kind of volume of sales? It could be, if you succeed very well in the coming years.

Hannu Martola
22:53 - 23:24

We intend to have double-digit growth in that area. How well the plans realize is a little bit challenging to give any exact number there, except that I can say that there is a lot of testing being done currently in both the US and Europe for our Detection Technology TFT-enabled equipment.

Ewa
23:26 - 23:46

All right. Maybe a similar question about India, because now you have made some deliveries from there. You have new capabilities or, let's say, government approval for medical. If I understood correctly, could you quantify a little bit how you expect to grow your sales from India?

Hannu Martola
23:46 - 25:20

Yeah. From our point of view, India is very promising. We see opportunities for medical, both for CT later on. By the way, there are not many CT machines or equipment made in very high volumes today, but that also applies to TFT, for which India is already a sizable market in medical applications. We see opportunities for security. India is still in the process of building more than 100 new airports. So that's a big need for all kinds of aviation products. We see opportunities in India for cargo. India has 7,500 km of shoreline, for example, with very undeveloped harbor infrastructure. So that is a good opportunity for harbor infrastructure. India needs to invest into high-speed trains. And that is also yielding opportunities in cargo inspection at harbors. And altogether, it should be a quite nice and balanced portfolio: medical, security, industrial, and even the battery sector and so on. India basically has to be able to create internal competence and production for all key technologies. And that is battery storage, medical, dental, security, and so on. So, there are a lot of opportunities. Of course, the challenge for India is then the money, how much and how fast can they invest into the infrastructure to be able to develop the economy.

Ewa
25:22 - 25:55

All right. Understood that it's a massive opportunity, but you don't want to provide any forward-looking guidance. Last question from me is about the cash flows. I think my colleague already asked a little bit about this, but I just wanted to understand, do you still need to raise the inventory levels in the second half of the year, or are we now at the level where you feel comfortable, even though the situation in the component market is tight?

Hannu Martola
25:55 - 26:09

Yeah, I think in the big scale, we start to be at the peak. I mean, of course there can be small ups or downs and so on, but I mean, it is at a stable level. And then next year we should be starting to see some melting of the inventory.

Ewa
26:10 - 26:11

All right. Thanks.

Operator
26:14 - 26:21

Thank you. Let's take some online questions. So how much TFT sales is coming from outside industrial.

Hannu Martola
26:23 - 27:13

Or TFT sales outside the industrial sector? So the question is how much TFT sales is coming from outside industrial. That is a good question. It's not very sizable because we've just started some first deliveries for medical. So basically, TFT I would bet. And now it is just my guess it is like 90% industrial so far. It started with industrial. We are working with a lot of EV companies, battery inspection firms, and some electronics companies. And we might see in the future also some security deals there. Let let let's see. The big thing is getting, and this is more long-term, the medical and dental markets opened for Detection Technology outside of China. So Europe and the US.

Operator
27:15 - 27:24

Thank you. How do you plan to improve profitability during the second half, given that the product mix is something that you cannot directly impact?

Hannu Martola
27:25 - 27:35

Yeah. Well, first, I think the product mix can improve as a mix, but we need to increase the top line.

Operator
27:40 - 27:46

Thank you. Do you expect a change in your sales mix in the second half?

Hannu Martola
27:47 - 27:57

Not very much. Well, like I said, the sales mix is probably a little bit better from the point of view of margins. But I mean, not very much.

Operator
27:59 - 28:00

Thank you. That is all.

Hannu Martola
28:03 - 28:11

Thank you. Well, I think we are finished. I thank you very much and wish you a great day. Thank you for watching.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…